← Back to graph
Supplement

pau d'arco taheebo

Selected indexed studies

  • Safety and tolerability of Pau d' Arco (Tabebuia avellanedae) for primary dysmenorrhea: A single-arm, open-label trial on adults ages 18-45. (Adv Integr Med, 2022) [PMID:36960315]
  • Single Dose Administration of Taheebo Polyphenol Enhances Endurance Capacity in Mice. (Sci Rep, 2018) [PMID:30279507]
  • Tabebuia impetiginosa: A Comprehensive Review on Traditional Uses, Phytochemistry, and Immunopharmacological Properties. (Molecules, 2020) [PMID:32962180]

_Worker-drafted node — pending editorial review._

Connections

pau d'arco taheebo helps

Sources

Local graph